All In Biotech

Drug Trial Radar · NCT07007637

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Multicenter, Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 19, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

835

Planned (sponsor's estimate)

Start

Jun 27, 2025

Primary completion

Jun 13, 2028

Study completion Jun 13, 2028

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Jun 6, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • SonelokimabDrug

    Sonelokimab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Long-term safety and tolerability of sonelokimab: Adverse events (AEs) following treatment with sonelokimabTime frame: 2.5-3 years
  2. Long-term safety and tolerability of sonelokimab: Treatment emergent adverse events (TEAEs)Time frame: 2.5-3 years
  3. Long-term safety and tolerability of sonelokimab: Adverse events of special interest (AESIs)Time frame: 2.5-3 years
  4. Long-term safety and tolerability of sonelokimab: Discontinuation of sonelokimab treatment due to AEsTime frame: 2.5-3 years
  5. Long-term safety and tolerability of sonelokimab: Clinically significant changes in clinical laboratory parametersTime frame: 2.5-3 years
  6. Long-term safety and tolerability of sonelokimab: Clinically significant changes in vital signs and standard 12-lead electrocardiogramTime frame: 2.5-3 years

Locations

166 sites in 16 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Birmingham, Alabama

  • Clinical Site

    North Little Rock, Arkansas

  • Clinical Site

    Los Angeles, California

  • Clinical Site

    Northridge, California

  • Clinical Site

    Aventura, Florida

  • Clinical Site

    Coral Gables, Florida

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Hollywood, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Miami, Florida

  • Clinical Site

    Ocala, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Macon, Georgia

  • Clinical Site

    Sandy Springs, Georgia

  • Clinical Site

    Skokie, Illinois

  • Clinical Site

    West Dundee, Illinois

  • Clinical Site

    Columbus, Indiana

  • Clinical Site

    New Albany, Indiana

  • Clinical Site

    Plainfield, Indiana

  • Clinical Site

    Louisville, Kentucky

  • Clinical Site

    Murray, Kentucky

  • Clinical Site

    Metairie, Louisiana

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Boston, Massachusetts

  • Clinical Site

    Ann Arbor, Michigan

  • Clinical Site

    Canton, Michigan

  • Clinical Site

    Clarkston, Michigan

  • Clinical Site

    Waterford, Michigan

  • Clinical Site

    New Brighton, Minnesota

  • Clinical Site

    Omaha, Nebraska

  • Clinical Site

    Las Vegas, Nevada

  • Clinical Site

    New York, New York

  • Clinical Site

    New York, New York

  • Clinical Site

    The Bronx, New York

  • Clinical Site

    Fargo, North Dakota

  • Clinical Site

    Boardman, Ohio

  • Clinical Site

    Columbus, Ohio

  • Clinical Site

    Dayton, Ohio

  • Clinical Site

    Oklahoma City, Oklahoma

Showing 40 of 166 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.